Do you want to read an article? Please log in or register.
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
Migraine and Headache
RECOMMENDED
Related content
Migraine and Headache
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Headache.
Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD
doi: 10.1111/head.13929.
Migraine and Headache
The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response
Headache
Broessner G, Reuter U, Bonner JH, Dodick DW, Hallström Y, Picard H, Zhang F, Lenz RA, Klatt J, Mikol DD
doi: 10.1111/head.13929
RECOMMENDED
Migraine and Headache
Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study
doi: 10.1177/0333102419835459.
RECOMMENDED
Migraine and Headache
Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache
Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R
doi: 10.1111/head.14036
Migraine and Headache
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study
Neurology.
Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA
doi: 10.1212/
Migraine and Headache
Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine
Headache.
Gonzalez-Martinez A, Rodríguez Vázquez E, de la Red Gallego H, García-Azorín D, Gallego de La Sacristana M, Guerrero Peral ÁL, Gago-Veiga AB
doi: 10.1111/head.13693.
RECOMMENDED
Migraine and Headache
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II
★ 2
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 3
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Headache.
Dodick DW, Lipton RB, Ailani J, Halker Singh RB, Shewale AR, Zhao S, Trugman JM, Yu SY, Viswanathan HN
doi: 10.1111/head.13766.
Migraine and Headache
Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study
Headache
Barbanti P, Aurilia C, Egeo G, Fofi L, Cevoli S, Colombo B, Filippi M, Frediani F, Bono F, Grazzi L, Salerno A, Mercuri B, Carnevale A, Altamura C, Vernieri F
doi: 10.1111/head.14032
Migraine and HeadacheAnxiety and Depression
Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study
Headache
Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E, Bigal ME, Bibeau K, Buse DC
doi: 10.1111/head.14097